These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 861931)

  • 1. Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia.
    Lee SH; Caron N; Kimball AP
    Cancer Res; 1977 Jul; 37(7 Pt 1):1953-5. PubMed ID: 861931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N; Lee SH; Kimball AP
    Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE; Au-Yeung TH
    Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin.
    LePage GA; Worth LS; Kimball AP
    Cancer Res; 1976 Apr; 36(4):1481-5. PubMed ID: 946595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
    Cass CE; Tan TH; Selner M
    Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3.
    Suling WJ; Rice LS; Shannon WM
    Cancer Treat Rep; 1978 Mar; 62(3):369-73. PubMed ID: 647695
    [No Abstract]   [Full Text] [Related]  

  • 7. Recovery of 2'-deoxycoformycin-inhibited adenosine deaminase of mouse erythrocytes and leukemia L1210 in vivo.
    Agarwal RP
    Cancer Res; 1979 Apr; 39(4):1425-7. PubMed ID: 421226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
    Plunkett W; Cohen SS
    Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of drug metabolism by a prodrug: 9-beta-D-arabinofuranosyladenine 5'-valerate as an inhibitor of adenosine deaminase.
    Lipper RA; Machkovech SM; Drach JC; Higuchi WI
    Mol Pharmacol; 1978 Mar; 14(2):366-9. PubMed ID: 642934
    [No Abstract]   [Full Text] [Related]  

  • 11. Potentiation by 2'-deoxycoformycin of the inhibitory effect by 3'-deoxyadenosine (cordycepin) on nuclear RNA synthesis in L1210 cells in vitro.
    Glazer RI; Lott TJ; Peale AL
    Cancer Res; 1978 Aug; 38(8):2233-8. PubMed ID: 307428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the cytotoxicity and metabolism of 4-amino-3-carboxamido-1-(beta-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine using inhibitors of adenosine kinase and adenosine deaminase.
    Wotring LL; Townsend LB
    Cancer Res; 1979 Aug; 39(8):3018-23. PubMed ID: 222442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine deaminase inhibition for immunosuppression.
    Chassin MM; Chirigos MA; Johns DG; Adamson RH
    N Engl J Med; 1977 May; 296(21):1232. PubMed ID: 854065
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    White EL; Shaddix SC; Brockman RW; Bennett LL
    Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse.
    Ho DH; Pincus C; Carter CJ; Benjamin RS; Freireich EJ; Bodey GP
    Cancer Treat Rep; 1980; 64(4-5):629-33. PubMed ID: 6968622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the effects of infusion of enzyme inhibitors on mouse adenosine deaminase.
    Trotta PP; Ahland MP; Brown GF; Balis ME
    Mol Pharmacol; 1978 Jan; 14(1):199-209. PubMed ID: 625284
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
    Cass CE; Selner M; Phillips JR
    Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the relationship between adenosine deaminase and immune function.
    Burridge PW; Paetkau V; Henderson JF
    J Immunol; 1977 Aug; 119(2):675-8. PubMed ID: 301901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Adamson RH; Zaharevitz DW; Johns DG
    Pharmacology; 1977; 15(1):84-9. PubMed ID: 840892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.